Zacks: Analysts Anticipate Strongbridge Biopharma PLC (SBBP) Will Post Quarterly Sales of $1.76 Million

Equities research analysts forecast that Strongbridge Biopharma PLC (NASDAQ:SBBP) will post $1.76 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Strongbridge Biopharma PLC’s earnings, with estimates ranging from $1.11 million to $2.96 million. The business is scheduled to issue its next earnings results on Friday, December 22nd.

According to Zacks, analysts expect that Strongbridge Biopharma PLC will report full year sales of $1.76 million for the current year, with estimates ranging from $3.18 million to $8.11 million. For the next year, analysts forecast that the company will post sales of $14.29 million per share, with estimates ranging from $9.39 million to $21.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Strongbridge Biopharma PLC.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). The company had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million.

Several analysts have commented on SBBP shares. Zacks Investment Research downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Strongbridge Biopharma PLC in a research note on Wednesday, May 17th. ValuEngine raised Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Finally, Oppenheimer Holdings, Inc. started coverage on Strongbridge Biopharma PLC in a research note on Thursday. They set an “outperform” rating and a $12.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.94.

A number of institutional investors have recently added to or reduced their stakes in SBBP. Broadfin Capital LLC boosted its position in Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock valued at $14,163,000 after buying an additional 87,125 shares during the last quarter. Vanguard Group Inc. acquired a new position in Strongbridge Biopharma PLC during the second quarter valued at about $474,000. Northern Trust Corp acquired a new position in Strongbridge Biopharma PLC during the second quarter valued at about $1,462,000. Citigroup Inc. acquired a new position in Strongbridge Biopharma PLC during the second quarter valued at about $338,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Strongbridge Biopharma PLC during the second quarter valued at about $449,000.

Strongbridge Biopharma PLC (SBBP) traded up 6.82% during mid-day trading on Friday, reaching $7.05. The company had a trading volume of 35,393 shares. The company’s market capitalization is $249.11 million. Strongbridge Biopharma PLC has a 12 month low of $2.00 and a 12 month high of $8.85. The firm’s 50 day moving average price is $6.86 and its 200-day moving average price is $4.63.

WARNING: “Zacks: Analysts Anticipate Strongbridge Biopharma PLC (SBBP) Will Post Quarterly Sales of $1.76 Million” was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.thestockobserver.com/2017/08/12/zacks-analysts-anticipate-strongbridge-biopharma-plc-sbbp-will-post-quarterly-sales-of-1-76-million.html.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply